Kumho HT, Inc. announced that it has received KRW 77.00016205 billion in funding from Korea Fixed-Income Investment Advisory, Lumimicro Co., Ltd, Feelux Co., Ltd, Gemini Investment Corporation and other investors
April 08, 2019
Share
On April 8, 2019, Kumho HT, Inc. (KOSE:A214330) closed the transaction. The company received KRW 7,000,000,000 in its twelfth and final tranche closing through issuance of 6th series unregistered coupon unguaranteed private convertible bonds.
Vivozon Pharmaceutical Co Ltd , formerly Vivozon Healthcare Inc, is a Korea-based company mainly engaged in the manufacture and sale of finished pharmaceutical products. The Company operates its business through three segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of finished medicines such as external skin preparations, antipyretic analgesic, anti-inflammatory drugs and antidiabetic drugs. The Optical Business segment is engaged in the manufacture and sale of finished products and lighting module sets such as general lighting and automotive lighting using light emitting diode (LED) light sources. The Cosmetics Business segment is engaged in the manufacture and sale of cosmetics and cosmetic ingredients.
Kumho HT, Inc. announced that it has received KRW 77.00016205 billion in funding from Korea Fixed-Income Investment Advisory, Lumimicro Co., Ltd, Feelux Co., Ltd, Gemini Investment Corporation and other investors
VIVOZON PHARMACEUTICAL CO., LTD. 
